MUMBAI, India, Aug. 12 -- Intellectual Property India has published a patent application (202637053838 A) filed by Actinogen Medical Limited on April 28, 2026, for Tablet Formulation.
Inventors include Lawson Jr. , Allen Lee; Li, Fujun; and Malefyt, Thomas Robert.
The application for the patent was published on August 07, 2026, under issue no. 32/2026.
Abstract: Xanamem, also known as UE2343, is an effective inhibitor of 11ß-hydroxysteroid dehydrogenase type 1 (11ß-HSD1). Due to its inhibitory action, Xanamem has been proposed as a treatment of disorders that are ameliorated by the inhibition of 11 ß-HSD1, such as metabolic syndrome, cardiovascular disorders, and CNS disorders. The present 5 disclosure relates to the formulation of Xanamem and excipients, particularly lactose and microcrystalline cellulose, as immediate-release tablet formulations.
Disclaimer: Curated by HT Syndication.
